Impower010 nct02486718
Witryna28 maj 2024 · We report the primary disease-free survival (DFS) results from the pre-planned interim analysis of IMpower010, a randomized phase 3 open-label trial of … Witryna中华医学杂志, 2024,103(14): 1074-1081.DOI: 10.3760/cma.j.cn112137-20241212-02628
Impower010 nct02486718
Did you know?
Witryna20 wrz 2024 · IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II-IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed PD-L1 on 1% or more of tumour cells, and no new safety signals. WitrynaPrevious findings from the Phase III IMpower010 ( NCT02486718) trial demonstrated a statistically significant improved disease-free survival (DFS) with atezolizumab compared to best supportive care (BSC) in patients with resected PD-L1 TC ≥1% stage II-IIIA non-small cell lung cancer (NSCLC) following platinum-based chemotherapy. 5 The …
Witryna23 mar 2024 · IMpower010 is a global, multicenter, open-label, randomized trial (NCT02486718), which is comparing the safety and efficacy of atezolizumab and BSC … Witryna1 cze 2024 · IMpower010 is a trial in patients with early stage disease, patients with stage IB, with tumor size of at least four centimeters, II and IIIA, according to the TNM …
Witryna23 sty 2024 · Efficacy was demonstrated in a multi-center, randomized, open-label trial (IMpower010, NCT02486718) in patients with stage IB (tumors ≥ 4 cm) through stage … Witryna2 lip 2024 · Disease-free survival in IMpower010 trial: adjuvant atezolizumab in NSCLC - YouTube Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, …
WitrynaNCT02486718 (active, not recruiting). Findings Between Oct 7, 2015, and Sept 19, 2024, 1280 patients were enrolled after complete resection. 1269 received ... To our knowledge, the data from IMpower010 are the first to . emerge from the phase 3 studies of adjuvant immunotherapy in stage IB–IIIA NSCLC. Patients with completely resected
Witryna15 paź 2024 · The decision was supported by data from the phase 3 IMpower010 trial (NCT02486718), which showed that the median disease-free survival (DFS) was not yet reached (95% CI, ... philly union covidWitrynaIMpower010 (NCT02486718) showed that adjuvant atezo improved disease-free survival (DFS) vs BSC in pts with PD-L1 tumour cell (TC) ≥1% stage II-IIIA NSCLC. While a ctDNA positive (+) status post-surgery (Post-OP ctDNA) conferred poor prognosis, atezo was beneficial vs BSC irrespective of Post-OP ctDNA status (Zhou ESMO-IO 2024). ... philly union rumorsWitryna12 lip 2024 · IMPower010 is randomized Phase III study that compare one year of adjuvant atezolizumab versus observation in patient with stage IB, II and III, non-small … philly union standingsWitryna10 wrz 2024 · IMpower010 (NCT02486718) enrolled patients with completely resected, stage IB to IIIA NSCLC with an ECOG performance status of 0 or 1, who had undergone lobectomy/pneumonectomy, and had tumor tissue available for PD-L1 analysis. If patients had stage IB tumors, they had to be 4 cm or greater. philly up - port macquarieWitrynaClinical Trial: NCT02486718 - My Cancer Genome Clinical Trials / Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive … philly union shopWitryna20 wrz 2024 · Exploratory results from the phase 3 IMpower010 trial (NCT02486718) show that adjuvant treatment with atezolizumab (Tecentriq) achieved an improvement in disease-free survival (DFS) and time to locoregional and distant relapse compared with best supportive care (BSC) in prespecified subgroups of PD-L1–positive patients with … philly union recordWitryna3 mar 2024 · In the adjuvant setting, Impower010 is the first phase 3 study to demonstrate DFS improvement with adjuvant atezolizumab in completely resected stage IB to IIIA NSCLC ... Impower010 (NCT02486718) IB (4 cm)-IIIA after Adj CT: Atezolizumab: DFS: PEARLS/KEYNOTE-091 (NCT02504372) Resected stage IB … phillyutah.com